ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Dapsone (systemic): Drug information

Dapsone (systemic): Drug information
(For additional information see "Dapsone (systemic): Patient drug information" and see "Dapsone (systemic): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • MAR-Dapsone;
  • RIVA-Dapsone
Pharmacologic Category
  • Antibiotic, Miscellaneous
Dosing: Adult
Aphthous ulcers, severe

Aphthous ulcers, severe (off-label use): Oral:

Initial: 25 mg daily for 3 days; increase dose in increments of 25 mg daily every 3 days up to 100 mg daily for 3 days, then increase by 25 mg daily every 7 days up to 150 mg daily. Administer in 2 divided doses (75 mg dose is administered in 3 divided doses).

Maintenance: 100 to 150 mg daily in 2 divided doses with or without concomitant colchicine (Lynde 2009; Rogers 1982).

Bullous pemphigoid

Bullous pemphigoid (alternative agent) (off-label use): Oral: 1 to 1.5 mg/kg/day, with or without immunosuppressive therapy (Ref).

Bullous systemic lupus erythematosus

Bullous systemic lupus erythematosus (off-label use): Oral: 50 mg once daily initially, with or without immunosuppressive therapy; range 25 to 200 mg daily (Contestable 2014; Fabbri 2003).

Dermatitis herpetiformis

Dermatitis herpetiformis (adjunctive agent):

Note: Management involves a combination of a strict lifelong gluten-free diet and drug therapy (Antiga 2015; Salmi 2019).

Oral: Initial: 25 to 50 mg daily; may increase as needed to 100 to 200 mg daily to achieve full control. Once rash is controlled, dose may be gradually tapered to a minimum maintenance dosage with eventual discontinuation based on clinical response (Antiga 2015; Salmi 2019).

Immune thrombocytopenia

Immune thrombocytopenia (alternative agent) (off-label use): Oral: 50 to 100 mg daily or 1 to 2 mg/kg/day; duration of therapy is ≥21 days (ASH [Neunert 2019]; Damodar 2005; Godeau 1997; Provan 2010).

Leprosy

Leprosy: Oral: 100 mg once daily as part of an appropriate combination regimen for 12 months for tuberculoid (paucibacillary) disease and 24 months for lepromatous (multibacillary) disease (NHDP [HRSA 2018]). Note: For resource-limited settings, the World Health Organization recommends 6 months for tuberculoid and 12 months for lepromatous (WHO 2018).

Pemphigus vulgaris

Pemphigus vulgaris (adjunctive agent) (off-label use): Oral: 25 mg daily for 7 days, then increase dose in increments of 25 mg daily every 7 days up to 100 mg daily for 7 days (4 weeks total therapy) with concomitant prednisone. Administer in 2 divided doses (a 75 mg dose is administered in 3 divided doses) (Azizi 2008). Usual dose range: 50 to 200 mg daily (Porro 2019). Note: If patient becomes lesion free, taper and discontinue gradually by decreasing dose 25 mg daily over 7 days. If no new lesions are seen, gradual taper is continued. If lesions recur, dose is increased by 25 mg daily at 7-day intervals until the patient develops no new lesions. Taper is usually ~4 weeks total (Azizi 2008).

Pneumocystis pneumonia in patients with HIV

Pneumocystis pneumonia in patients with HIV (alternative agent) (off-label use): Oral:

Prophylaxis (primary or secondary): 100 mg once daily or in 2 divided doses as monotherapy or 50 mg daily in combination with weekly pyrimethamine and leucovorin or 200 mg weekly in combination with weekly pyrimethamine and leucovorin. Continue until CD4 count >200 cells/mm3 for >3 months in response to antiretroviral therapy (ART); some experts discontinue prophylaxis in patients with CD4 counts between 100 and 200 cells/mm3 who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (HHS [OI Adult 2020]).

Treatment (mild to moderate disease): 100 mg once daily in combination with trimethoprim for 21 days (HHS [OI Adult 2020]).

Pyoderma gangrenosum

Pyoderma gangrenosum (alternative agent) (off-label use): Oral: 50 to 200 mg daily (Callen 2007; Din 2018; Vidal 2004).

Relapsing polychondritis

Relapsing polychondritis (off-label use): Oral: 25 to 200 mg daily (Damiani 1979; Ridgway 1979).

T. gondii encephalitis in patients with HIV

T. gondii encephalitis in patients with HIV (alternative to preferred therapy) (off-label use): Primary prophylaxis: Oral: 50 mg daily, in combination with weekly pyrimethamine and leucovorin or 200 mg weekly in combination with weekly pyrimethamine and leucovorin. Continue until CD4 count >200 cells/mm3 for >3 months in response to ART; some experts discontinue prophylaxis in patients with CD4 counts between 100 and 200 cells/mm3 who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (HHS [OI Adult 2020]).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary (Legendre 2012; expert opinion).

eGFR <30 mL/minute/1.73 m2: No dosage adjustment likely necessary based on pharmacokinetic properties (only 5% to 15% excreted in urine unchanged). However, use with caution and at the lower end of the indication-specific recommended dosing range when possible, with close monitoring of blood counts, as there are reports of dose-dependent hematologic toxicities (eg, methemoglobinemia, hemolysis) in patients with kidney impairment (Abouraya 2012; Lee 2015; Mannemuddhu 2021; Naik 2008; Nessim 2010; Serwin 2002; Tan 2020; Ward 1998; expert opinion).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzed (moderate Vd, moderate to high protein binding): Dose as for eGFR <30 mL/minute/1.73 m2 (expert opinion).

Peritoneal dialysis: Unlikely to be significantly dialyzed (moderate Vd, moderate to high protein binding): Dose as for eGFR <30 mL/minute/1.73 m2 (expert opinion).

CRRT: No dosage adjustment necessary (expert opinion).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (expert opinion).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (Legendre 2012)

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Dapsone (systemic): Pediatric drug information")

Dermatitis herpetiformis

Dermatitis herpetiformis: Infants, Children, and Adolescents: Oral: Initial: 0.5 to 2 mg/kg/day in 1 to 2 divided doses (Ermacora 1986; Kliegman 2016); maximum initial daily dose in adults: 50 mg/day; increase dose as needed to achieve control; usual adult dose: 300 mg/dose; once lesions controlled, some have reported that dose may be decreased as tolerated for chronic therapy to a reported range: 0.125 to 0.5 mg/kg/day (Ermacora 1986; Reunala 1984)

Idiopathic thrombocytopenic purpura, refractory

Idiopathic thrombocytopenic purpura (ITP), refractory: Limited data available: Children ≥3 years and Adolescents: Oral: 1 to 2 mg/kg/day for at least 2 months. Dosing based on two retrospective reviews. The first was a retrospective cohort analysis of adult and pediatric (age range: 3 to 61 years, including 35 patients <16 years) with chronic ITP (>6 months with diagnosis) who failed steroid therapy and observed an overall similar response rate for children (65.7%) and adults (Damodar 2005). Adverse effects occurred in three patients (one with acute hemolysis and two with an erythematous rash). The second was a small retrospective report of seven pediatric patients with acute or chronic refractory, symptomatic ITP (age range: 6 to 15 years) which also showed a similar response rate (60%); however, a higher incidence (two of seven patients [29%]) of methemoglobinemia was observed (Meeker 2003).

Leprosy

Leprosy (Hansen's disease): Note: Treatment should be managed in consultation with a leprosy expert; use of multidrug therapy is important to prevent drug resistance (Red Book [AAP 2018]). Recommended duration varies:

Paucibacillary (Tuberculoid) leprosy (1 to 5 patches):

National Hansen's Disease Program Recommendations: Infants, Children, and Adolescents: Oral: 1 mg/kg/dose once daily for 12 months; maximum dose: 100 mg/dose; use in combination with rifampin (NHDP [HRSA 2018]).

WHO Recommendations (WHO 2016):

Infants and Children <10 years and weighing <20 kg: Oral: 2 mg/kg/dose once daily for 6 months; use in combination with rifampin

Children ≥10 years and Adolescents ≤14 years:

20 to 40 kg: Oral: 25 mg once daily for 6 months; use in combination with rifampin

>40 kg: Oral: 50 mg once daily for 6 months; use in combination with rifampin

Adolescents >14 years: Oral: 100 mg once daily for 6 months; use in combination with rifampin

Multibacillary (Lepromatous) leprosy (≥6 patches):

National Hansen's Disease Program Recommendations: Infants, Children, and Adolescents: Oral: 1 mg/kg/dose once daily for 24 months; maximum dose: 100 mg/dose; use in combination with rifampin and clofazimine (NHDP [HRSA 2018]).

WHO Recommendations (WHO 2016):

Infants and Children <10 years and weighing <20 kg: Oral: 2 mg/kg/dose once daily for 12 months; use in combination with rifampin and clofazimine

Children ≥10 years and Adolescents ≤14 years:

20 to 40 kg: Oral: 25 mg once daily for 12 months; use in combination with rifampin and clofazimine

>40 kg: Oral: 50 mg once daily for 12 months; use in combination with rifampin and clofazimine

Adolescents >14 years: Oral: 100 mg once daily for 12 months; use in combination with rifampin and clofazimine

Linear IgA bullous dermatosis

Linear IgA bullous dermatosis (LABD): Limited data available: Infants, Children, and Adolescents: Oral: 0.5 to 2 mg/kg/day in 1 to 2 divided doses with or without prednisone (Kenani 2009; Kliegman 2016; Thappa 2003); may increase if needed at weekly intervals until symptoms controlled; maximum reported daily dose: 4 mg/kg/day (Thappa 2003); usual adult dose: 25 to 150 mg/day (Fortuna 2012).

Pneumocystis jirovecii pneumonia, alternative agent

Pneumocystis jirovecii pneumonia (PCP), alternative agent (patients unable to take trimethoprim/sulfamethoxazole):

Prophylaxis (primary or secondary): Multiple regimens (daily or weekly dosing) and combinations presented

HIV-exposed/-infected: Oral:

Infants and Children: 2 mg/kg/dose once daily (maximum daily dose: 100 mg/day) or 4 mg/kg/dose once weekly (maximum weekly dose: 200 mg/week) (HHS [OI pediatric 2016])

Adolescents: 100 mg/day in 1 or 2 divided doses as monotherapy or 50 mg once daily in combination with weekly pyrimethamine and leucovorin or 200 mg once weekly in combination with weekly pyrimethamine and leucovorin; monotherapy should not be used in patients who are seropositive for Toxoplasma gondii (HHS [OI adult 2018])

Hematopoietic stem cell transplant recipient (CDC/IDSA [Tomblyn 2009]): Oral:

Infants and Children: 2 mg/kg/dose once daily; maximum dose: 100 mg/dose

Adolescents: 100 mg/day in 1 or 2 divided doses

Treatment, mild to moderate disease: Limited data available: Infants, Children, and Adolescents (HIV-exposed/-infected): Oral: 2 mg/kg/dose once daily in combination with trimethoprim for 21 days; maximum dose: 100 mg/dose (HHS [OI adult 2018]; HHS [OI pediatric 2016])

Toxoplasma gondii, primary prophylaxis, HIV-exposed/-infected patients, alternative agent

Toxoplasma gondii , primary prophylaxis, HIV-exposed/-infected patients, alternative agent (patients unable to tolerate trimethoprim/sulfamethoxazole): Note: Multiple regimens (daily or weekly dosing), combinations, and dosing units (mg/kg, mg/m2) presented; use caution.

Infants and Children: Oral: 2 mg/kg/dose or 15 mg/m2/dose once daily in combination with pyrimethamine and leucovorin; maximum dose: 25 mg/dose (HHS [OI pediatric 2016])

Adolescents: Oral: 50 mg once daily in combination with weekly pyrimethamine and leucovorin or 200 mg once weekly in combination with weekly pyrimethamine and leucovorin (HHS [OI adult 2018])

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, some clinicians have suggested that no adjustment is necessary (Aronoff 2007).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions (Significant): Considerations
Blood dyscrasias

Dapsone is associated with methemoglobinemia, hemolytic anemia, neutropenia, and agranulocytosis. There are rare reports of aplastic anemia (Ref) and pancytopenia (Ref).

Methemoglobinemia: Symptoms may be absent or mild and nonspecific (eg, malaise (Ref), headache, fatigue, tachycardia, (Ref) but can be severe with dyspnea, cyanosis, and hypoxia (Ref), and it has been fatal (Ref). Mean peak methemoglobin of 7.6% (range: 2.1% to 34.1%) of hemoglobin has been described (Ref). A "saturation gap" between SpO2A and SaO2, chocolate-brown arterial blood, and cyanosis presenting as pasty brown mucous membranes are considered characteristic (Ref). Dapsone discontinuation with supplemental oxygen as indicated generally leads to resolution within 2 weeks (Ref); however, cases have taken longer to resolve (Ref). Reported incidences vary depending on case definitions: Cyanosis or hypoxia (O2 saturation ≤95%) with methemoglobin level ≥3% occurred in 20% of those taking dapsone in one study (Ref). Methemoglobin levels >1.5% occurred 46% in another study (Ref).

Hemolytic anemia: Dapsone-induced hemolytic anemia may be found on routine monitoring or after presentation with mild symptoms (eg, fatigue, exertional dyspnea) in those without G6PD deficiency (Ref). Patients with G6PD deficiency present with more severe symptoms (eg, tachycardia, tachypnea, mild hypoxia in room air) (Ref). Decreased hemoglobin has been reported in patients without G6PD deficiency (Ref); however, patients with G6PD deficiency experience more significant reductions (Ref)). Hemolytic anemia has been fatal in resource limited settings despite transfusion (Ref). Recovery usually occurs 8 to 10 days after discontinuation but has taken up to ~3 months (Ref). Up to 10% may require packed red cells (Ref).

Neutropenia: Neutropenia (Ref) can be severe (Ref) and has been fatal (Ref). ANC generally recovers ≤1 month after discontinuation (Ref).

Agranulocytosis: Approximately 90% of cases present with fever and other symptoms of infection while the remainder are detected on routine CBC monitoring (Ref). Absolute neutrophil counts as low as 0 cells/mm3 have been reported (Ref) and has been fatal (Ref). Neutrophils normalize a median of 10 days after discontinuation (Ref).

Mechanism:

Methemoglobinemia: Dose-related; hydroxylamine metabolite oxidizes ferrous iron (Fe2+) in heme to ferric iron (Fe3+), converting hemoglobin to methemoglobin which has reduced oxygen carrying capacity. NADH dependent cytochrome b5 reductase, NADPH-dependent methemoglobin reductase, ascorbic acid, and glutathione mediated removal of methemoglobin are overwhelmed and the proportion of methemoglobin to hemoglobin is increased (Ref).

Hemolytic anemia: Dose-related; hydroxylamine metabolite and nitroso-dapsone, formed during conversion of hemoglobin to methemoglobin, generate reactive oxygen radicals. In G6PD deficiency, these accumulate and directly damage red blood cell membranes leading to hemolysis. The hydroxylamine metabolite can directly affect phosphorylation of membrane proteins, leading to hemolysis in those without G6PD deficiency (Ref).

Neutropenia and Agranulocytosis: Non–dose-related; hydroxylamine is toxic to bone marrow myeloid cells (Ref)

Onset:

Methemoglobinemia: Varied; ranges from 1 day (Ref) to 5 months (Ref) or longer (Ref).

Hemolytic anemia: Varied; presenting within 24 to 72 hours then worsening until days 7 to 8 in individuals with G6PD deficiency (Ref). May present later in individuals without G6PD deficiency with reports ranging from 11 to 71 days (Ref).

Neutropenia: Varied; typical time to onset ≤7 days (Ref).

Agranulocytosis: Varied; median duration of dapsone treatment before symptom development was 56 days (range: 6 to 133 days) (Ref).

Risk factors:

Methemoglobinemia:

• More common with higher doses (eg, overdose) (Ref), but has been reported with treatment and prophylactic doses (Ref)

• Kidney impairment (Ref)

• Mixed evidence for low cytochrome b5 reductase (Cb5R) levels or heterozygosity for Cb5R deficiency (Ref)

• G6PD deficiency (Ref)

• Concurrent methemoglobinemia-inducing agents (Ref)

• For symptoms:

- Anemia (Ref)

- Blood loss (Ref)

- Coronary artery disease (Ref)

- Lung disease or pneumonia (Ref)

- Sepsis (Ref)

- Abnormal hemoglobin species (eg, carboxyhemoglobin, sulfhemoglobin, or sickle hemoglobin) (Ref)

Hemolytic anemia:

• Dose (Ref)

• G6PD deficiency (Ref)

• Low ideal body weight (Ref)

• Kidney impairment (Ref)

• Compromised bone marrow (eg, hematopoietic stem cell transplantation) (Ref)

• Hemoglobin H disease (Ref)

Neutropenia:

• Older age (Ref)

• Underlying disease (Ref)

• Females (Ref)

• Concurrent medications (Ref)

Agranulocytosis:

• Older age (>60 years) (Ref)

• Non-Caucasian descent (Ref)

• Preexisting severe inflammatory conditions (eg, dermatitis herpetiformis) (Ref)

• N-acetyltransferase deficiency (Ref)

Hepatic effects

Hepatic injury ranges from mild increased serum transaminases to fulminant hepatic failure (Ref). Hyperbilirubinemia may occur more frequently in G6PD deficient patients (Ref). Hepatotoxicity is most often associated with signs of hypersensitivity, as part of drug rash with eosinophilia and systemic symptoms (DRESS) (Ref). Liver injury is typically cholestatic or mixed (Ref). Most cases resolve within 2 to 8 weeks of discontinuing dapsone; although, severe cholestatic injury may be prolonged (Ref).

Mechanism: Unknown: Non–dose-related; possibly hypersensitivity mechanism, through metabolism to a reactive, toxic metabolite (Ref).

Onset: Varied; duration of therapy prior to onset of hepatotoxicity is typically within a few days to weeks; although, can be delayed up to 5 months (Ref). A shorter onset occurs upon rechallenge (Ref).

Risk factors:

• HLA-B*13:01 has been associated with hepatotoxicity (Ref)

Hypersensitivity reactions (delayed)

Drug rash with eosinophilia and systemic symptoms (DRESS; previously known as dapsone or sulfone syndrome) (Ref) has been reported. In most cases, predominant hepatotoxicity (Ref) is noted, although pancreatitis (Ref), acute kidney injury (Ref), or eosinophilic pneumonitis (Ref) may also occur. Fever, along with other cutaneous reactions may be reported, including fixed drug eruption, photosensitivity, maculopapular rash, and erythematous plaques (Ref). Additional serious cutaneous adverse reactions (SCARs) include Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) (Ref) and acute generalized exanthematous pustulosis (AGEP) (Ref). Following discontinuation of dapsone, resolution occurs within days to several months (mean: 27 days); although, may result in fatality in 10% of cases (Ref). In some patients, hypothyroidism and/or diabetes mellitus may develop months after discontinuation (Ref).

Mechanism: Delayed hypersensitivity reactions: Non–dose-related, immunologic. Delayed hypersensitivity reactions are T-cell mediated (Ref).

Onset: Delayed hypersensitivity reactions: Varied. Serious cutaneous adverse reactions, usually occur 1 to 8 weeks after initiation (Ref). A mean of a ~32 days has been reported with dapsone but may also occur up to 6 months after initiation (Ref).

Risk factors:

• HLA-B*13:01 has been associated with SCARs (Ref).

• Cross-reactivity may occur in patients with a history of a hypersensitivity reaction to sulfonamide antibiotics (eg, sulfamethoxazole/trimethoprim) (Ref), although dapsone may be considered as an option in patients with mild reactions to sulfonamide antibiotics (Ref).

• Younger patients may be at an increased risk for development of DRESS; older patients have decreased production of toxic metabolites due to decreased enzyme activity associated with aging (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Tachycardia

Endocrine & metabolic: Albuminuria, hypoalbuminemia (without proteinuria)

Gastrointestinal: Abdominal pain, nausea, vomiting

Genitourinary: Male infertility

Hematologic & oncologic: Reticulocytosis

Infection: Infectious mononucleosis (infectious mononucleosis-like syndrome)

Nervous system: Headache, insomnia, psychomotor impairment, psychosis, vertigo

Neuromuscular & skeletal: Lupus-like syndrome

Ophthalmic: Blurred vision

Otic: Tinnitus

Renal: Nephrotic syndrome, renal papillary necrosis

Postmarketing:

Dermatologic: Acute generalized exanthematous pustulosis (Vas 2013), fixed drug eruption (Sauvetre 2015), maculopapular rash (Kosseifi 2006), phototoxicity (Kar 2008), Stevens-Johnson syndrome (Tempark 2017), toxic epidermal necrolysis (Tempark 2017)

Gastrointestinal: Pancreatitis (Das 2014)

Hematologic & oncologic: Agranulocytosis (St Clair 2021), aplastic anemia (Meyerson 1994), decreased hemoglobin (Khatri 2020, Murphy 2016), hemolysis (Khatri 2020, Murphy 2016), hemolytic anemia (Khatri 2020, Murphy 2016), methemoglobinemia (Shenouda 2022), neutropenia (Hsieh 2020), pancytopenia (Abdur Raheem 2022)

Hepatic: Cholestatic jaundice, hepatic failure (Devarbhavi 2018), hepatitis (Devarbhavi 2018), hyperbilirubinemia (Pamba 2012), increased serum transaminases (Abidi 2006)

Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Kang 2021)

Nervous system: Peripheral neuropathy (Waldinger 1984)

Renal: Acute kidney injury (Pai 2017)

Respiratory: Eosinophilic pneumonitis (Kinehara 2015)

Miscellaneous: Fever (Kosseifi 2006)

Contraindications

Hypersensitivity to dapsone or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Advanced amyloidosis of the kidneys.

Warnings/Precautions

Concerns related to adverse effects:

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Anemia: Use with caution in patients with severe anemia; treat prior to therapy.

• Diabetes mellitus: Dapsone may artificially lower HbA1c by reducing erythrocyte survival time through hemolysis (Lai 2012).

• Leprosy: New or severe dermatological reactions require discontinuation of therapy; however, leprosy reactional states (eg, erythema nodosum leprosum) do not require discontinuation.

Special populations:

• G6PD deficiency: Use with caution in patients with G6PD deficiency; dose-related hemolysis and methemoglobinemia may occur.

• Hemoglobin M deficiency: Use with caution in patients with hemoglobin M deficiency; dose-related hemolysis may occur.

• Methemoglobin reductase deficiency: Use with caution in patients with methemoglobin reductase deficiency; dose-related hemolysis may occur.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 25 mg, 100 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Dapsone Oral)

25 mg (per each): $2.47 - $4.25

100 mg (per each): $3.02 - $4.17

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 100 mg

Administration: Adult

Oral: Administer with meals if GI upset occurs.

Administration: Pediatric

Oral: May administer with meals if GI upset occurs.

Use: Labeled Indications

Dermatitis herpetiformis: Treatment of dermatitis herpetiformis.

Leprosy: Treatment of leprosy (due to susceptible strains of Mycobacterium leprae).

Use: Off-Label: Adult

Aphthous ulcers (severe); Bullous pemphigoid; Bullous systemic lupus erythematosus; Immune thrombocytopenia; Pemphigus vulgaris; Pneumocystis pneumonia prophylaxis in patients with HIV; Pneumocystis pneumonia treatment in patients with HIV; Pyoderma gangrenosum; Relapsing polychondritis; Toxoplasma gondii encephalitis prophylaxis in patients with HIV

Medication Safety Issues
Sound-alike/look-alike issues:

Dapsone may be confused with Diprosone

Metabolism/Transport Effects

Substrate of CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M. Risk D: Consider therapy modification

Atazanavir: Dapsone (Systemic) may enhance the adverse/toxic effect of Atazanavir. Specifically, the risk of hyperbilirubinemia may be increased. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

CYP3A4 Inducers (Moderate): May decrease the serum concentration of Dapsone (Systemic). Risk C: Monitor therapy

CYP3A4 Inducers (Strong): Dapsone (Systemic) may enhance the adverse/toxic effect of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic). Risk C: Monitor therapy

Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Risk C: Monitor therapy

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

Methotrexate: Dapsone (Systemic) may increase the serum concentration of Methotrexate. Management: Avoid coadministration of dapsone and methotrexate if possible. If coadministration is required, monitor closely for methotrexate toxicities (eg, hematological, gastrointestinal, nephrotoxicity toxicities). Risk D: Consider therapy modification

Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Risk C: Monitor therapy

Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Trimethoprim: May increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim. Risk C: Monitor therapy

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Reproductive Considerations

In uncontrolled studies and published surveys, dapsone did not affect female reproduction. Male infertility is noted as an adverse event in the dapsone product labeling.

Pregnancy Considerations

Dapsone crosses the placenta (Brabin 2004).

Per the manufacturer, dapsone has not shown an increased risk of congenital anomalies when given during all trimesters of pregnancy. Dapsone may displace bound bilirubin in the neonate, increasing the risk of kernicterus. In addition, there are case reports of hemolytic anemia in fetus/infant following maternal treatment. Neonatal care providers should be informed if dapsone is used near delivery (HHS [OI adult 2019]).

Dapsone may be used in pregnant women requiring maintenance therapy of either leprosy or dermatitis herpetiformis. Dapsone may be used as an alternative agent for management of Pneumocystis jirovecii pneumonia (PCP) or Toxoplasma gondii encephalitis in pregnant, patients living with HIV (HHS [OI Adult 2019]).

Breastfeeding Considerations

Dapsone is present in breast milk.

Dapsone can be detected in the serum of nursing infants. Hemolytic anemia has been reported in a breastfed infant (Sanders 1982). Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, considering the importance of treatment to the mother. Other sources consider dapsone, when used in usual doses, to be compatible with breastfeeding. Breastfed infants should be monitored for hemolysis and jaundice especially premature infants or infants <1 month of age. Avoid breastfeeding infants with G-6-PD deficiency (WHO 2002).

Monitoring Parameters

Check G6PD levels (prior to initiation); CBC (weekly for first month, monthly for 6 months and semiannually thereafter); liver function tests (baseline and periodic). Monitor patients for signs of jaundice, hemolysis, and blood dyscrasias.

May artificially lower HbA1c by reducing erythrocyte survival time through hemolysis. If the patient has diabetes, consider alternative methods to monitor diabetes control other than HbA1c (Lai 2012).

Mechanism of Action

Competitive antagonist of para-aminobenzoic acid (PABA) and prevents normal bacterial utilization of PABA for the synthesis of folic acid

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Rapid and almost complete.

Protein binding: Dapsone: 70% to 90%; Metabolite: ~99% (Zuidema 1986).

Distribution: Vd: 1.5 L/kg (Zuidema 1986).

Metabolism: Hepatic (acetylation and hydroxylation); forms multiple metabolites (Zuidema 1986).

Half-life elimination: Children: 15.1 hours (Mirochnick 1993); Adults: 28 hours (range: 10 to 50 hours).

Time to peak: 4 to 8 hours.

Excretion: Urine (~85%, mainly as metabolites [5 to 15% unchanged (Zuidema 1986)]).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Avlosulfon;
  • (AR) Argentina: Daps | Dapsona Lazar;
  • (AT) Austria: Dapson Fatol;
  • (BD) Bangladesh: Lepsone;
  • (BR) Brazil: Furp dapsona;
  • (CH) Switzerland: Dapson Fatol;
  • (CO) Colombia: Dapsulon;
  • (CZ) Czech Republic: Avlosulfon;
  • (DE) Germany: Dapson Fatol | Dapson tillomed;
  • (DK) Denmark: Dapson Scanpharm;
  • (EC) Ecuador: Dapsona Lazar;
  • (EE) Estonia: Dapson Fatol | Dapson Scanpharm;
  • (ES) Spain: Sulfona;
  • (FI) Finland: Avlosulfon;
  • (GB) United Kingdom: Dapsone cox;
  • (GR) Greece: Dapson mae;
  • (ID) Indonesia: Dds;
  • (IL) Israel: Avlosulfon;
  • (JP) Japan: Lectisol;
  • (KR) Korea, Republic of: Novopon | Taiguk dapsone;
  • (LT) Lithuania: Avlosulfon | Dapson Fatol;
  • (LV) Latvia: Avlosulfon | Dapson | Dapson Fatol;
  • (MX) Mexico: Dapsoderm-x | Dapsone nos | Novasulfon;
  • (MY) Malaysia: Ccm dapsone;
  • (NL) Netherlands: Dapson | Dapson mae | Dapson ratiopharm | Dapson Tiofarma;
  • (NO) Norway: Dapson | Dapson Fatol;
  • (PH) Philippines: Lepravir;
  • (PK) Pakistan: Dermosone;
  • (PL) Poland: Avlosulfon | Dapson;
  • (PT) Portugal: Dapsona | Sulfona;
  • (RU) Russian Federation: Dapson | Dapson Fatol;
  • (SI) Slovenia: Dapson | Dapson Fatol;
  • (TH) Thailand: Avlosulfon | Dopsan | Servidapsone;
  • (TW) Taiwan: Avlosulfon | Servidapsone | X Dapsone;
  • (UG) Uganda: Agodaps | Lapsone;
  • (VN) Viet Nam: Medi dapsone
  1. Abidi MH, Kozlowski JR, Ibrahim RB, Peres E. The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. Hematol Oncol. 2006;24(3):164-5. doi:10.1002/hon.780 [PubMed 16639690]
  2. Abdur Raheem J, Unnisa A, Iqubal M. Dapsone as a detrimental cause of necrotizing fasciitis with severe resistant neutropenia: A Case Report. Cureus. 2022;14(3):e23076. doi:10.7759/cureus.23076 [PubMed 35464541]
  3. Abouraya M, Sacco JC, Hayes K, Thomas S, Kitchens CS, Trepanier LA. Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity. J Clin Pharmacol. 2012;52(2):272-278. doi:10.1177/0091270010393343 [PubMed 21422237]
  4. Aczone prescribing information, Allergan, Inc, Irvine CA, February 2012.
  5. Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol. 2005;32(11):883-889. doi:10.1111/j.1346-8138.2005.tb00865.x [PubMed 16361748]
  6. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.
  7. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657-665. doi:10.7326/0003-4819-146-9-200705010-00009 [PubMed 17470834]
  8. Antiga E, Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clin Cosmet Investig Dermatol. 2015;8:257-265. doi:10.2147/CCID.S69127 [PubMed 25999753]
  9. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  10. Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004;83(5):265-273. doi:10.1097/01.md.0000141096.00377.3f [PubMed 15342970]
  11. Azizi A, Lawaf S. The management of oral pemphigus vulgaris with systemic corticosteroids and dapsone. J Dent Res Dent Clin Dent Prospects. 2008;2(1):33-37. doi:10.5681/joddd.2008.007 [PubMed 23285328]
  12. Barclay JA, Ziemba SE, Ibrahim RB. Dapsone-induced methemoglobinemia: a primer for clinicians. Ann Pharmacother. 2011;45(9):1103-1115. doi:10.1345/aph.1Q139 [PubMed 21852596]
  13. Barnett ED, Pelton SI, Mirochnick M, Cooper ER. Dapsone for prevention of Pneumocystis pneumonia in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J. 1994;13(1):72-74. [PubMed 8170736]
  14. Bartakke SP, Sampagar AA, Reddy NA, Kangle R. Dapsone induced agranulocytosis and hemolytic anemia in immune thrombocytopenic purpura. Indian J Pediatr. 2020;87(10):856. doi:10.1007/s12098-020-03226-x [PubMed 32140985]
  15. Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm. 2018;75(3):97-104. doi:10.2146/ajhp160961 [PubMed 29305344]
  16. Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. Drug Saf. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2 [PubMed 31020549]
  17. Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med. 1996;100(6):611-616. doi:10.1016/s0002-9343(96)00008-3 [PubMed 8678080]
  18. Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689-1704. doi:10.1111/jdv.18220 [PubMed 35766904]
  19. Borrás-Blasco J, Conesa-García V, Navarro-Ruiz A, Devesa P, Matarredona J, Marín-Jiménez F. Pure red cell aplasia associated with dapsone therapy. Ann Pharmacother. 2005;39(6):1137-1138. doi:10.1345/aph.1E349 [PubMed 15870135]
  20. Brabin BJ, Eggelte TA, Parise M, Verhoeff F. Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes. Drug Saf. 2004;27(9):633-648. doi:10.2165/00002018-200427090-00002 [PubMed 15230645]
  21. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  22. Cai F, Lucas M, Yun J. Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01. Intern Med J. 2018;48(3):363-364. doi:10.1111/imj.13730 [PubMed 29512326]
  23. Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am. 2007;33(4):787-802. doi:10.1016/j.rdc.2007.07.016 [PubMed 18037117]
  24. Chalasani P, Baffoe-Bonnie H, Jurado RL. Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. South Med J. 1994;87(11):1145114-6. doi:10.1097/00007611-199411000-00018 [PubMed 7973902]
  25. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146(12):1373-1379. doi:10.1001/archdermatol.2010.198 [PubMed 20713773]
  26. Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology. 2001;162(1):53-60. doi:10.1016/s0300-483x(01)00360-2 [PubMed 11311458]
  27. Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol. 2014;15(6):517-524. doi:10.1007/s40257-014-0098-0 [PubMed 25358414]
  28. Damiani JM, Levine HL. Relapsing polychondritis—report of ten cases. Laryngoscope. 1979;89:929-946. [PubMed 449538]
  29. Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients. Eur J Haematol. 2005;75(4):328-331. doi:10.1111/j.1600-0609.2005.00545.x [PubMed 16146539]
  30. Dapsone tablets, USP [prescribing information]. East Brunswick, NJ: Rising Pharmaceuticals Inc; January 2023.
  31. Das AK, Jawed Q. Drug-induced acute pancreatitis: a rare manifestation of an incomplete "dapsone syndrome". Indian J Pharmacol. 2014;46(4):455-457. doi:10.4103/0253-7613.135967 [PubMed 25097293]
  32. Devarbhavi H, Raj S, Joseph T, Singh R, Patil M. Features and treatment of dapsone-induced hepatitis, based on analysis of 44 cases and literature review. Clin Gastroenterol Hepatol. 2017;15(11):1805-1807. doi:10.1016/j.cgh.2017.05.031 [PubMed 28552804]
  33. Devarbhavi H, Patil M, Reddy VV, Singh R, Joseph T, Ganga D. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. Liver Int. 2018;38(7):1322-1329. doi:10.1111/liv.13662 [PubMed 29222960]
  34. Devarbhavi H, Patil M, Menon M. Association of human leukocyte antigen-B*13:01 with dapsone-induced liver injury. Br J Clin Pharmacol. 2022;88(3):1369-1372. doi:10.1111/bcp.15054 [PubMed 34427944]
  35. Din RS, Tsiaras WG, Li DG, Mostaghimi A. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. J Drugs Dermatol. 2018;17(10):1058-1060. [PubMed 30365585]
  36. Dunyo S, Sirugo G, Sesay S, et al. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One. 2011;6(6):e17371. doi:10.1371/journal.pone.0017371 [PubMed 21666744]
  37. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med. 1998;339(26):1889-1895. doi:10.1056/NEJM199812243392604 [PubMed 9862944]
  38. Ermacora E, Prampolini L, Tribbia G, et.al. Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol. 1986;15(1):24-30. doi:10.1016/s0190-9622(86)70137-0 [PubMed 3722506]
  39. Esbenshade AJ, Ho RH, Shintani A, Zhao Z, Smith LA, Friedman DL. Dapsone-induced methemoglobinemia: a dose-related occurrence? Cancer. 2011;117(15):3485-3492. doi:10.1002/cncr.25904 [PubMed 21246536]
  40. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  41. Ezhilarasan D. Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia. Drug Chem Toxicol. 2021;44(3):330-333. doi:10.1080/01480545.2019.1679829 [PubMed 31631707]
  42. Fabbri P, Cardinali C, Giomi B, et al. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4(7):449-465. doi:10.2165/00128071-200304070-00002 [PubMed 12814335]
  43. Fanello CI, Karema C, Avellino P, et al. High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS One. 2008;3(12):e4031. doi:10.1371/journal.pone.0004031 [PubMed 19112496]
  44. Fernando M, Kankananarachchi I, Navabalasooriyar P, Herath B, Punchihewa P. A case of dapsone-induced severe agranulocytosis causing life-threatening skin sepsis in a Sri Lankan child with borderline leprosy: A success story! Case Rep Med. 2019;2019:2314379. doi:10.1155/2019/2314379 [PubMed 31198424]
  45. Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol. 2012;30(1):38-50. doi:10.1016/j.clindermatol.2011.03.008 [PubMed 22137225]
  46. Garcia A, Yi NJ, Lee KB, et al. Fulminant hepatitis linked to dapsone hypersensitivity syndrome requiring urgent living donor liver transplantation: a case report. Pediatr Transplant. 2014;18(7):E240-E245. doi:10.1111/petr.12343. Erratum in: Pediatr Transplant. 2018;22(5):e13224. [PubMed 25156688]
  47. Gluth MB, Witman PM, Thompson DM. Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis. Int J Pediatr Otorhinolaryngol. 2004;68(7):965-970. doi:10.1016/j.ijporl.2004.02.014 [PubMed 15183590]
  48. Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997;97(2):336-339. doi:10.1046/j.1365-2141.1997.412687.x [PubMed 9163598]
  49. Guragain S, Upadhayay N, Bhattarai BM. Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study. Clin Pharmacol. 2017;9:73-78. doi:10.2147/CPAA.S135846 [PubMed 28721106]
  50. Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol. 2009;10(6):383-96. doi:10.2165/11310740-000000000-00000 [PubMed 19824739]
  51. Hama N, Abe R, Gibson A, Phillips EJ. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155-1167.e5. doi:10.1016/j.jaip.2022.02.004 [PubMed 35176506]
  52. Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: Recommended Treatment Regimens. Updated April 2018. Accessed June 8, 2021. https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html.
  53. Hocking DR. Neonatal haemolytic disease due to dapsone. Med J Aust. 1968;1(26):1130-1131. doi:10.5694/j.1326-5377.1968.tb29209.x [PubMed 4969972]
  54. Holtzer CD, Flaherty JF Jr, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacotherapy. 1998;18(4):831-5. [PubMed 9692656]
  55. Hörnsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol. 1990;126(7):919-22. doi:10.1001/archderm.1990.01670310081011 [PubMed 2360840]
  56. Hsieh CY, Tsai TF. Drug-induced neutropenia during treatment of non-neoplastic dermatologic diseases: A review. Clin Drug Investig. 2020;40(10):915-926. doi:10.1007/s40261-020-00956-w [PubMed 32691244]
  57. Kabra NS, Nanavati RN, Srinivasan G. Neonatal methemoglobinemia due to transplacental transfer of dapsone. Indian Pediatr. 1998;35(6):553-555. [PubMed 10216653]
  58. Kang DY, Yun J, Lee SY, et al; Korean severe cutaneous adverse reactions consortium. A nationwide study of severe cutaneous adverse reactions based on the multicenter registry in Korea. J Allergy Clin Immunol Pract. 2021;9(2):929-936.e7. doi:10.1016/j.jaip.2020.09.011 [PubMed 32961314]
  59. Kar BR. Dapsone-induced photosensitivity: a rare clinical presentation. Photodermatol Photoimmunol Photomed. 2008;24(5):270-271. doi:10.1111/j.1600-0781.2008.00372.x [PubMed 18811870]
  60. Keerty D, Eaton K, Haynes E. Dapsone-induced hypoxia. Cureus. 2020;12(7):e9334. doi:10.7759/cureus.9334 [PubMed 32714715]
  61. Kenani N, Mebazaa A, Denguezli M, et al. Childhood linear IgA bullous dermatosis in Tunisia. Pediatric Dermatology. 2009;26(1):28-33. doi:10.1111/j.1525-1470.2008.00817.x [PubMed 19250401]
  62. Khatri A, Lal M R S, Bhaskaran MC. Dapsone-associated hemolytic anemia in renal transplant recipients with normal glucose-6-phosphate-dehydrogenase levels. Am J Ther. 2022;29(3):e369-e372. doi:10.1097/MJT.0000000000001252 [PubMed 32947344]
  63. Kinehara Y, Kijima T, Inoue K, et al. Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluid. Intern Med. 2015;54(7):827-831. doi:10.2169/internalmedicine.54.3406 [PubMed 25832951]
  64. Kishida Y, Kameyama J, Nei M, Hashimoto T, Baba K. Linear IgA bullous dermatosis of neonatal onset: case report and review of the literature. Acta Paediatr. 2004;93(6):850-854. [PubMed 15244240]
  65. Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.
  66. Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.
  67. Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy G. The dapsone hypersensitivity syndrome revisited: A potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol. 2006;1:9. doi:10.1186/1745-6673-1-9 [PubMed 16756657]
  68. Lai YC, Wang CS, Wang YC, Hsu YL, Chuang LM. Falsely decreased HbA1c in a type 2 diabetic patient treated with dapsone. J Formos Med Assoc. 2012;111(2):109-112. doi:10.1016/j.jfma.2012.01.007 [PubMed 22370290]
  69. Lee I, Barton TD, Goral S, et al. Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant. 2005;5(11):2791-2795. doi:10.1111/j.1600-6143.2005.01079.x [PubMed 16212642]
  70. Lee SM, Geetha D. Dapsone induced hemolysis in a patient with ANCA associated glomerulonephritis and normal G6PD level and implications for clinical practice: case report and review of the literature. Springerplus. 2015;4:29. doi:10.1186/s40064-015-0816-y [PubMed 25628986]
  71. Legendre DP, Muzny CA, Swiatlo E. Hansen’s disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy. 2012;32(1):27-37. doi:10.1002/PHAR.1009 [PubMed 22392826]
  72. Letko E, Zafirakis P, Baltatzis S, Voudouri A, Livir-Rallatos C, Foster CS. Relapsing polychondritis: a clinical review. Semin Arthritis Rheum. 2002;31(6):384-395. doi:10.1053/sarh.2002.32586 [PubMed 12077711]
  73. Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019;155(6):666-672. doi:10.1001/jamadermatol.2018.5360 [PubMed 30916737]
  74. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol. 2012;92(2):194-199. doi:10.2340/00015555-1268 [PubMed 22307940]
  75. Lynde CB, Bruce AJ, Rogers RS 3rd. Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol. 2009;145(3):273-276. doi:10.1001/archdermatol.2008.591 [PubMed 19289756]
  76. Mannemuddhu SS, Ali R, Kadhem S, Ruchi R. Unusual cause of persistent dyspnea in a patient with nephrotic syndrome: Dapsone-induced methemoglobinemia. CEN Case Rep. 2021;10(3):336-340. doi:10.1007/s13730-020-00565-8 [PubMed 33417185]
  77. Mar-Dapsone (dapsone) [product monograph]. Ottawa, Ontario, Canada: Marcan Pharmaceuticals, Inc; September 2018.
  78. May SM, Motosue MS, Park MA. Dapsone is often tolerated in HIV-infected patients with history of sulfonamide antibiotic intolerance. J Allergy Clin Immunol Pract. 2017;5(3):831-833. doi:10.1016/j.jaip.2016.11.011 [PubMed 28034550]
  79. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990;323(12):776-782. doi:10.1056/NEJM199009203231202 [PubMed 2392131]
  80. Meeker ND, Goldsby R, Terrill KR, Delaney KS, Slayton WB. Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25(2):173-175. doi:10.1097/00043426-200302000-00019 [PubMed 12571474]
  81. Meyerson MA, Cohen PR. Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus. Mayo Clin Proc. 1994;69(12):1159-1162. doi:10.1016/s0025-6196(12)65768-1 [PubMed 7967777]
  82. Mimura MA, Hirota SK, Sugaya NN, Sanches JA Jr, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics (Sao Paulo). 2009;64(3):193-198. doi:10.1590/s1807-59322009000300008 [PubMed 19330244]
  83. Mirochnick M, Michaels M, Clarke D, Breña A, Regan AM, Pelton S. Pharmacokinetics of dapsone in children. J Pediatr. 1993;122(5 pt 1):806-809. doi:10.1016/s0022-3476(06)80033-8 [PubMed 8496767]
  84. Mitsides N, Green D, Middleton R, et al. Dapsone-induced methemoglobinemia in renal transplant recipients: more prevalent than previously thought. Transpl Infect Dis. 2014;16(1):37-43. doi:10.1111/tid.12161 [PubMed 24215452]
  85. Murphy AG, Grossman SA. Acute hemolysis in a patient with a newly diagnosed glioblastoma. CNS Oncol. 2016;5(3):125-129. doi:10.2217/cns-2015-0009 [PubMed 27230975]
  86. Naik PM, Lyon GM 3rd, Ramirez A, et al. Dapsone-induced hemolytic anemia in lung allograft recipients. J Heart Lung Transplant. 2008;27(11):1198-202. doi:10.1016/j.healun.2008.07.025 [PubMed 18971091]
  87. National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management (CG183). 2014; clinical guideline 183. https://www.nice.org.uk/guidance/cg183
  88. Nessim SJ, Lipman ML. The case/cyanosis in a hemodialysis patient. Kidney Int. 2010;78(3):327-328. doi:10.1038/ki.2010.152 [PubMed 20631737]
  89. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966 [PubMed 31794604]
  90. Ognibene AJ. Agranulocytosis due to dapsone. Ann Intern Med. 1970;72(4):521-524. doi:10.7326/0003-4819-72-4-521 [PubMed 5437633]
  91. Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH. High prevalence of dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. Bone Marrow Transplant. 2012;47(3):399-403. doi:10.1038/bmt.2011.83 [PubMed 21478917]
  92. Pai S, Munshi R, Nayak C. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus. Indian J Pharmacol. 2017;49(5):396-398. doi:10.4103/ijp.IJP_764_16 [PubMed 29515281]
  93. Pamba A, Richardson ND, Carter N, et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. 2012;120(20):4123-4133. doi:10.1182/blood-2012-03-416032 [PubMed 22993389]
  94. Park HJ, Park JW, Kim SH, et al; Allergy Work Group of KAAACI. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses. Expert Opin Drug Saf. 2020;19(10):1349-1356. doi:10.1080/14740338.2020.1796965 [PubMed 32700588]
  95. Pertel P, Hirschtick R. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin Infect Dis. 1994;18(4):630-632. doi:10.1093/clinids/18.4.630 [PubMed 8038322]
  96. Poirot E, Vittinghoff E, Ishengoma D, et al. Risks of hemolysis in glucose-6-phosphate dehydrogenase deficient infants exposed to chlorproguanil-dapsone, mefloquine and sulfadoxine-pyrimethamine as part of intermittent presumptive treatment of malaria in infants. PLoS One. 2015;10(11):e0142414. doi:10.1371/journal.pone.0142414 [PubMed 26599634]
  97. Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(suppl 1):20-32. doi:10.1590/abd1806-4841.2019940206 [PubMed 31166407]
  98. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186. doi:10.1182/blood-2009-06-225565 [PubMed 19846889]
  99. Rassner M, Jung J, Schneider J, Wäsch R, Engelhardt M. Dapsone-induced hemolytic anemia in multiple myeloma: Case report of various differential diagnoses. Clin Lymphoma Myeloma Leuk. 2020;20(11):e821-e825. doi:10.1016/j.clml.2020.06.021 [PubMed 32753123]
  100. Reunala T, Kosnai I, Karpati S, Kuitunen P, Török E, Savilahti E. Dermatitis herpetiformis: jejunal findings and skin response to gluten free diet. Arch Dis Child. 1984;59(6):517-522. doi:10.1136/adc.59.6.517 [PubMed 6742871]
  101. Ridgway HB, Hansotia PL, Schorr WF. Relapsing polychondritis: unusual neurological findings and therapeutic efficacy of dapsone. Arch Dermatology. 1979;115(1):43. doi:10.1001/archderm.115.1.43 [PubMed 760656 ]
  102. Rogers LR, Oppelt P, Nayak L. Hemolytic anemia associated with dapsone PCP prophylaxis in GBM patients with normal G6PD activity. Neuro Oncol. 2020;22(6):892-893. doi:10.1093/neuonc/noaa026 [PubMed 32047930]
  103. Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol. 1982;6(2):215-223. doi:10.1016/s0190-9622(82)70014-3 [PubMed 7037880]
  104. Salmi TT. Dermatitis herpetiformis. Clin Exp Dermatol. 2019;44(7):728-731. doi:10.1111/ced.13992 [PubMed 31093998]
  105. Sanders SW, Zone JJ, Foltz RL, Tolman KG, Rollins DE. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med. 1982;96(4):465-466. doi:10.7326/0003-4819-96-4-465 [PubMed 7065565]
  106. Satapornpong P, Pratoomwun J, Rerknimitr P, et al. HLA-B*13 :01 is a predictive marker of dapsone-induced severe cutaneous adverse reactions in Thai patients. Front Immunol. 2021;12:661135. doi:10.3389/fimmu.2021.661135. [PubMed 34017337]
  107. Sauvetre G, MahÉvas M, Limal N, et al. Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. Am J Hematol. 2015;90(10):E201-E202. doi:10.1002/ajh.24068 [PubMed 26120067]
  108. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol. 2002;9(2):123-126. doi:10.1097/00062752-200203000-00007 [PubMed 11844995]
  109. Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31. doi: 10.1186/s13601-015-0073-8 [PubMed 26339470]
  110. Serwin AB, Myśliwiec H, Laudańska H, Chodynicka B. Linear IgA bullous dermatosis in a diabetic patient with chronic renal failure. Int J Dermatol. 2002;41(11):778-780. doi:10.1046/j.1365-4362.2002.01620_1.x [PubMed 12453003]
  111. Shenouda M, Padilla M, Silva J, Castillo H, Austin A. Dapsone-induced methemoglobinemia: A case report. Cureus. 2022;14(2):e22466. doi:10.7759/cureus.22466 [PubMed 35371634]
  112. Stavola JJ, Noel GJ. Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1993;12(8):644-647. doi:10.1097/00006454-199308000-00004 [PubMed 8414776]
  113. St Claire K, Kaul S, Caldito EG, Kramer ON, Griffin T, Albrecht J. Dapsone-induced agranulocytosis: symptoms may alert more reliably than the current blood monitoring protocol. Br J Dermatol. 2021;184(5):962-963. doi:10.1111/bjd.19708 [PubMed 33270224]
  114. Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299-1305. doi:10.1111/bjd.15649 [PubMed 28494097]
  115. Tan YS, Rajahram GS. The blue man: A case of dapsone-induced methaemoglobinaemia. International Journal of Infectious Diseases. 2020; 101(suppl 1): 161-162. doi: 10.1016/j.ijid.2020.09.436
  116. Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: A systematic review and meta-analysis. JAMA Dermatol. 2018;154(4):441-446. doi:10.1001/jamadermatol.2017.6484 [PubMed 29541744]
  117. Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea. 2007;26(2):215-219. doi:10.1097/ICO.0b013e31802eb078 [PubMed 17251816]
  118. Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017;27(12):429-437. doi:10.1097/FPC.0000000000000306 [PubMed 28885988]
  119. Thappa DM, Jeevankumar B. Chronic bullous dermatosis of childhood. Postgrad Med J. 2003;79(934):437. doi:10.1136/pmj.79.934.437 [PubMed 12954953]
  120. Thornton YS, Bowe ET. Neonatal hyperbilirubinemia after treatment of maternal leprosy. South Med J. 1989;82(5):668. doi:10.1097/00007611-198905000-00037 [PubMed 2717998]
  121. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143-1238. doi:10.1016/j.bbmt.2009.06.019 [PubMed 19747629]
  122. Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther. 1988;245(1):274-279. [PubMed 3129552]
  123. Urbancic KF, Pisasale D, Wight J, Trubiano JA. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients. Transpl Infect Dis. 2018;20(6):e12968. doi:10.1111/tid.12968 [PubMed 30030892]
  124. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Updated October 2015. http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf.
  125. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed April 30, 2020. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
  126. Vas A, Laws P, Marsland A, McQuillan O. Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone. Int J STD AIDS. 2013;24(9):745-747. doi:10.1177/0956462413482813 [PubMed 24026795]
  127. Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatolog Treat. 2004;15(3):146-152. doi:10.1080/09546630410031909 [PubMed 15204146]
  128. Waldinger TP, Siegle RJ, Weber W, Voorhees JJ. Dapsone-induced peripheral neuropathy. Case report and review. Arch Dermatol. 1984;120(3):356-359. [PubMed 6322702]
  129. Ward KE, McCarthy MW. Dapsone-induced methemoglobinemia. Ann Pharmacother. 1998;32(5):549-553. doi:10.1345/aph.17003 [PubMed 9606476]
  130. World Health Organization. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 2012;(968):1-61, 1 p following 61. [PubMed 22970604]
  131. Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25-32. doi:10.1001/archderm.144.1.25 [PubMed 18209165]
  132. Williams S, MacDonald P, Hoyer JD, Barr RD, Athale UH. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer. 2005;44(1):55-62. doi:10.1002/pbc.20164 [PubMed 15390276]
  133. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
  134. World Health Organization (WHO). Global Leprosy Strategy 2016-2020: Accelerating towards a leprosy-free world. August 2016. http://www.who.int/lep/resources/9789290225096/en/
  135. World Health Organization (WHO). Guidelines for the diagnosis, treatment and prevention of leprosy. Published 2018. Accessed April 19, 2021. https://apps.who.int/iris/handle/10665/274127.
  136. Zuidema J, Hilbers-Modderman ES, Merkus FW. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986;11(4):299-315. doi: 0.2165/00003088-198611040-00003 [PubMed 3530584]
Topic 9096 Version 361.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟